Latest news with #OrionPharma
The Australian
05-08-2025
- Business
- The Australian
Compumedics wins sales as broker lifts target ~140pc
Compumedics secures two lucrative sales for its Somfit sleep device with combined revenues approaching $2 million Sales to a leading CRO in US and a Finnish pharmaceutical company support strategy to expand in adjacent markets East Coast Research revises Compumedics target price to 75 cents per share, showing upside potential of 138.7% Special Report: Compumedics has secured lucrative multiple Somfit sales to leading pharmaceutical and clinical research organisations (CROs) in the US and Europe East Coast Research sees an almost 140% upside to its current target price. Compumedics (ASX: CMP), a global medical device company specialising in sleep, brain and ultrasonic blood flow monitoring, has inked a sale with a leading CRO for its Somfit devices. The company noted the devices will be used in a major US-based clinical drug trial with one of the world's largest pharmaceutical companies. Compumedics also secured a second sale with Finland-based global pharmaceutical firm Orion Pharma for deployment of Somfit devices across a multi-country, multi-centre clinical study in Europe. Somfit is a wearable device used for collecting physiological data during sleep with combined revenues from both sales approaching $2 million. The sales support the company's strategy to expand into adjacent markets, where Somfit's ability to collect electroencephalography (EEG) signals and provide insights into sleep stages and patterns provides a distinct advantage over traditional home sleep testing systems. The contracts also validate Somfit's clinical value proposition in the pharmaceutical sector, where understanding the effects of new drugs on sleep is becoming an increasingly important regulatory and research requirement. 'Building a diversified global business' Executive chairman and CEO Dr David Burton said the sales wins highlight the growing momentum Compumedics was seeing for Somfit in new market segments. 'The pharmaceutical clinical trial market is an ideal adjacency for our technology, and these early contracts, approaching $2 million in combined value, demonstrate Somfit's versatility beyond traditional home sleep testing,' 'This is another important step in building a diversified global business with multiple high growth pathways." Compumedics expects to build on this early traction, continuing engagement with major pharmaceutical companies and research institutions worldwide. Broker re-rates Compumedics following milestones and global expansion Meanwhile, East Coast Research has revised its target price for Compumedics to 75 cents per share, representing an upside potential of 138.7% from the share price at the time of its review and an 11.9% increase on its previous 67 cent target set in March. In its updated valuation, East Coast Research set a base case of 59 cents per share and an upside case of 92 cents, with a price-to-NAV (net asset value) of 0.42x. The Sydney-based equity research house said the re-rating reflected several key achievements, including: Record FY25 sales orders of $63.4m, up 22% YoY and return to profitability with $3m EBITDA for the financial year Validation of its world-first dual-use Orion LifeSpan MEG system Strong FY26 guidance with $70m in revenue and $9m in EBITDA supported by US launch of Somfit D, rising SaaS contributions and delivery of three MEG systems A $24.4 million pipeline secured through two long-term distribution agreements in China Broader entry into pharmaceutical trials 'These developments not only strengthen CMP's position in high-growth segments like SaaS and brain imaging but also significantly de-risk its revenue outlook and enhance its value proposition in the global medtech and connected health markets,' the broker noted. East Coast said Compumedics remained well-positioned for long-term value creation. This article was developed in collaboration with Compumedics, a Stockhead advertiser at the time of publishing. This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.
Associated Press
30-04-2025
- Business
- Associated Press
X-Chem Expands Strategic Collaboration With Orion Pharma to Accelerate Orion's Early Drug Discovery From Hit to Candidate
WALTHAM, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- X-Chem, a global leader in DNA-encoded library (DEL) technology and data-driven drug discovery, has announced an expanded collaboration with Orion Pharma. The agreement builds on an existing relationship and now extends the partnership from hit identification through to candidate selection. Under a new Technology Access Agreement, Orion will utilize X-Chem's integrated discovery capabilities, including DEL screening, AI-driven hit triage, and medicinal chemistry support, to drive multiple early-stage programs forward. This expanded engagement reflects years of collaboration and trust between the two companies. Through previous work together, X-Chem has delivered high-value insights and differentiated chemical matter to Orion's discovery teams. The renewed commitment is a strategic step forward in advancing small molecule discovery with greater efficiency and precision. 'X-Chem's flexible business model is enabling us to evaluate both new targets and revisit existing programs with enhanced tools,' said Heikki Käsnänen, Head of Molecular Prospecting and Modeling at Orion Pharma. 'We are applying their DEL-based screening technologies, as well as their expertise in AI and computational chemistry, to explore alternative routes for optimization. This approach is further supported by synthetic and medicinal chemistry to expand hit series and advance toward lead optimization.' X-Chem's platform combines advanced DEL capabilities with ArtemisAI, its proprietary artificial intelligence engine trained on the world's largest DEL datasets. Together with in-house computational and medicinal chemistry teams, the company helps partners make informed decisions earlier in the discovery process, reducing risk and improving outcomes. 'Our goal is to empower innovative companies like Orion to efficiently identify and progress high-quality drug candidates,' said Karen Lackey, CEO at X-Chem. 'This expanded partnership reflects a strong foundation of trust and a shared commitment to overcoming complex challenges in early discovery. By aligning our scientific expertise, we can help Orion move from hit to candidate with speed and confidence.' The collaboration reinforces X-Chem's position as a discovery partner with capabilities that extend well beyond traditional screening, offering end-to-end discovery solutions designed to accelerate success in small molecule drug discovery. About X-Chem X-Chem is a pioneer in data-driven small molecule drug discovery. By integrating DNA-encoded library (DEL) technology, artificial intelligence, and medicinal chemistry, X-Chem accelerates the path from target to clinical candidate. With a proven track record across complex targets and therapeutic areas, X-Chem delivers smarter hits, faster timelines, and reduced early-stage risk for pharmaceutical and biotech partners. Learn more at About Orion Pharma Orion is a globally operating Nordic pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. In 2024 Orion's net sales amounted to EUR 1,542 million and the company employed about 3,700 professionals worldwide, dedicated to building well-being. Orion's A and B shares are listed on Nasdaq Helsinki. Learn more at Media Contact: Alli Cooke [email protected] 616.258.5769
